EW Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.7B
-1.5%
1.7B
+5.6%
1.6B
+5.0%
1.6B
+1.1%
1.6B
Cost of Revenue
369.2M
-5.9%
392.4M
+8.2%
362.6M
+5.7%
343.0M
-0.6%
345.2M
Gross Profit
1.3B
-0.2%
1.3B
+4.9%
1.3B
+4.8%
1.2B
+1.5%
1.2B
Operating Expenses
1.0B
+25.4%
835.4M
+3.3%
808.4M
-28.4%
1.1B
+23.7%
913.3M
R&D
281.4M
+0.9%
278.9M
+5.9%
263.3M
-1.6%
267.7M
-4.6%
280.7M
SG&A
560.9M
-0.1%
561.2M
+7.5%
522.2M
-13.4%
602.9M
+17.2%
514.6M
Operating Income
299.1M
-41.7%
513.2M
+7.5%
477.6M
+393.4%
96.8M
-67.1%
294.6M
EBITDA
562.2M
+0.0%
562.2M
+1.2%
555.6M
+39.4%
398.7M
-14.1%
464.3M
Net Income
301.4M
+24.9%
241.4M
-36.6%
380.7M
+317.4%
91.2M
-68.6%
290.3M
EPS (Basic)
$0.53
+26.2%
$0.42
-36.4%
$0.66
+312.5%
$0.16
-68.0%
$0.50
EPS (Diluted)
$0.53
+26.2%
$0.42
-36.4%
$0.66
+312.5%
$0.16
-68.0%
$0.50
Shares (Diluted)
577.6M
+0.0%
577.6M
-0.5%
580.7M
-0.2%
581.8M
-0.7%
585.7M
Edwards Lifesciences (EW) — Financials